New Drug Shows Promise for Dog Dementia

Posted on


An estimated 40 percent of senior dogs 12 or older will develop some level of canine cognitive dysfunction, also known as dog dementia. A pilot clinical trial conducted for dogs with CCD looked at the drug Ropesalazine, which is a candidate for treating human Alzheimer’s patients.

According to the drug’s manufacturer, South Korea-based GNT Pharma, Ropesalazine showed efficacy in canine dementia patients, returning to a normal cognitive function and daily activity after eight weeks of treatment.

Thumbnail: Photography ©CatLane | Getty Images.

About the author

Jackie Brown is a freelance writer from Southern California who specializes in the pet industry. Reach her at jackiebrownwriter.wordpress.com.

Editor’s note: This article appeared in Dogster magazine. Have you seen the new Dogster print magazine in stores? Or in the waiting room of your vet’s office? Subscribe now to get Dogster magazine delivered straight to you! 

Read more about dog health and care on Dogster.com:





Source link

Also Read :   Abandoned cat, 17 years old, beaten by her owners refuses human touch until she realized she loved her – catsislove